Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
The European Commission granted marketing authorization for REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only authorized treatment for adults with FCS that does not require genetic confirmation of the condition. The authorization is supported by data from the Phase 3 PALISADE study, where the 25 mg dose demonstrated an 80% reduction in triglycerides and an 83% reduction in the incidence of acute pancreatitis compared to placebo.
Key figures
- Drug Name
- REDEMPLO (plozasiran)
- Phase Of Trial
- Phase 3
- Hyperglycemia rate
- 12.8%
- Triglyceride reduction
- 80%
- Acute pancreatitis incidence reduction
- 83%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.